Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios | Zendy

Rebecca Tay | Zendy; Arsela Prelaj | Zendy; Raffaele Califano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios

Author(s) -

Rebecca Tay,

Arsela Prelaj,

Raffaele Califano

Publication year - 2018

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2018.01.80

Subject(s) - atezolizumab , nivolumab , medicine , pembrolizumab , blockade , oncology , lung cancer , adverse effect , immunotherapy , immune checkpoint , immune system , ipilimumab , cancer , immunology , receptor

Immune checkpoint blockade has shown anti-tumour activity and improved survival in advanced non-small cell lung cancer (NSCLC). A number of anti-PD-1/PD-L1 and CTLA-4 monoclonal antibody agents have been evaluated in metastatic non-small cell lung cancer. Nivolumab, pembrolizumab and atezolizumab are currently approved for use in clinical practice due to demonstrated improvement in response rate, overall survival (OS) and quality of life (QoL) over standard chemotherapy. We present a series of cases that highlight the clinical challenges that these novel agents present. A review of rare immune-related adverse events (AEs), optimal treatment duration and patient selection will be presented. This series will also address real-life clinical scenarios such as treatment re-challenge and management of immune-related AEs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research